SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Share-based Compensation of $798000.0 for Q1 2026, up 58.02% year-over-year from $505000.0 in Q1 2025, and up 78.52% quarter-over-quarter from $447000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Share-based Compensation for 16 consecutive years, with $798000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 58.02% year-over-year to $798000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 41.18% YoY), while the FY2025 annual figure was $2.0 million, up 25.06% from the prior year.
- Share-based Compensation grew to $798000.0 in Q1 2026 per SLS's latest filing, from $447000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $798000.0 in Q1 2026 and bottomed at -$1.2 million in Q4 2023.
- Historically, Share-based Compensation has averaged $342333.3 across 5 years, with a median of $476000.0 in 2024.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 594.59% — and 2024, when it sank 35.02%.
- SELLAS Life Sciences' Share-based Compensation stood at $74000.0 in 2022, then tumbled by 1760.81% to -$1.2 million in 2023, then surged by 130.35% to $373000.0 in 2024, then rose by 19.84% to $447000.0 in 2025, then jumped by 78.52% to $798000.0 in 2026.
- Business Quant data shows SLS's Share-based Compensation at $798000.0 in Q1 2026, $447000.0 in Q4 2025, and $503000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Mn |
| Jun 30, 2026 | 1.02 Mn |
| Mar 31, 2026 | 798,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Mar 31, 2024 | 476,000.00 |